Specialized Research FDA Approved

Linaclotide

Also known as: Linzess, Constella, Linaclotida

Molecular Identifiers

Molecular Formula

C59H79N15O21S6

PubChem CID

16158208

Molecular Weight

1526.8 Da

Overview

Guanylate cyclase-C (GC-C) receptor agonist peptide, composed of 14 amino acids with three disulfide bonds and a molecular weight of approximately 1,526.8 Da. Approved for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Acts locally in the intestine with minimal systemic absorption.

Approved by the FDA as Linzess (2012) for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults.

Sequence (1 letter): CCEYCCNPACTGCY
Extended notation: Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly-Cys-Tyr

Half-life

~3-5 minutes (local, intestinal)

Administration Route

Oral

Category

Specialized Research

Mechanism of Action

  • Activation of the guanylate cyclase-C (GC-C) receptor on intestinal epithelial cells
  • Increased intracellular cGMP (cyclic guanosine monophosphate) production
  • Stimulation of chloride and bicarbonate secretion into the intestinal lumen
  • Increased intestinal fluid secretion and acceleration of transit
  • Reduction of visceral pain via extracellular cGMP signaling on afferent nerves
  • Inhibition of visceral afferent nociceptors

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter Value
Dose 72-290 mcg oral (subcutaneous research 100-500 mcg)
Frequency Once daily (oral)
Timing 30 minutes before the first meal of the day
Duration Continuous use (oral) or 4-8 weeks (research)

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

  • Diarrhea
  • Abdominal pain
  • Flatulence
  • Abdominal distension

Presentations & Preparation

Vials of Linaclotide found in the research market:

5 mg10 mg

Reconstitution

  • Diluent: Bacteriostatic water (for research formulation)
  • Volume: 1-2 ml per vial
  • For oral use, administer intact capsules — do not open or chew
  • For subcutaneous research, reconstitute with sterile diluent
  • Gently swirl until completely dissolved — never shake

Storage

  • Lyophilized: Refrigerated 2-8°C (research); room temperature for commercial capsules
  • Reconstituted: Refrigerated 2-8°C (up to 14 days)
  • Protect from moisture (capsules)
  • Keep in original packaging until use
  • Do not freeze after reconstitution
Reconstitution Calculator

Scientific Studies

Published studies on Linaclotide.

Related Peptides